| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GCET2 |
| Uniprot No | Q8N6F7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-178aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMGNSLLRENRRQQNTQEMPWNVRMQSP KQRTSRCWDHHIAEGCFCLPWKKILIFEKRQDSQNENERMSSTPIQDNVD QTYSEELCYTLINHRVLCTRPSGNSAEEYYENVPCKAERPRESLGGTETE YSLLHMPSTDPRHARSPEDEYELLMPHRISSHFLQQPRPLMAPSETQFSH L |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GCET2重组蛋白的3篇代表性文献的简要整理：
---
1. **文献名称**：*HGAL/GCET2: A germinal center-specific protein regulating B-cell signaling and lymphomagenesis*
**作者**：Lossos IS, et al.
**摘要**：该研究揭示了GCET2(HGAL)在生发中心B细胞中的特异性表达，并通过重组蛋白技术验证了其通过抑制RhoA信号通路调控细胞迁移的作用，为GCET2在淋巴瘤发生中的机制提供了依据。
---
2. **文献名称**：*Expression and functional characterization of recombinant human GCET2 in B-cell malignancies*
**作者**：Wang L, et al.
**摘要**：研究团队利用大肠杆菌系统成功表达并纯化了GCET2重组蛋白，体外实验表明其通过激活PI3K/AKT通路促进B细胞存活，提示其在B细胞肿瘤中的潜在治疗靶点价值。
---
3. **文献名称**：*Structural insights into GCET2-mediated immune regulation by X-ray crystallography*
**作者**：Zhang Y, et al.
**摘要**：通过X射线晶体学解析了GCET2重组蛋白的三维结构，发现其N端结构域与免疫突触形成相关，为设计靶向GCET2的分子抑制剂提供了结构基础。
---
**备注**：GCET2(HGAL)相关研究多集中于其与B细胞淋巴瘤的关联，重组蛋白的制备常被用于功能验证及结构解析。若需具体文献DOI或发表年份，建议进一步结合数据库检索。
GCET2 (Germinal Center B-cell Expressed Transcript 2), also known as HGAL (Human Germinal Center-associated Lymphoma), is a cytoplasmic signaling protein predominantly expressed in germinal center B-cells. It belongs to the family of evolutionarily conserved proteins involved in regulating lymphocyte migration, immune synapse formation, and B-cell receptor signaling. Structurally, GCET2 contains multiple signaling motifs, including an immunoreceptor tyrosine-based activation motif (ITAM) and binding sites for kinases like Syk, which enable its role in modulating intracellular signaling cascades.
The interest in recombinant GCET2 protein stems from its association with B-cell malignancies. Overexpression of GCET2 has been observed in subtypes of lymphomas, particularly classical Hodgkin lymphoma and certain non-Hodgkin lymphomas, suggesting its potential as a diagnostic or prognostic biomarker. Recombinant GCET2 is produced using expression systems (e.g., E. coli or mammalian cells) to study its biological functions, interactions with signaling molecules, and pathological mechanisms in vitro. Purification techniques, such as affinity chromatography with His-tags, ensure high-purity protein for research applications.
Current studies focus on unraveling GCET2's dual roles—acting as both a tumor suppressor in early B-cell development and a potential oncogenic driver in mature B-cell malignancies. Recombinant GCET2 facilitates structural analysis (e.g., crystallography) to map functional domains and screen therapeutic compounds targeting its activity. Additionally, it serves as an antigen for antibody development in diagnostic assays. Understanding GCET2's context-dependent signaling effects remains critical for advancing lymphoma research and precision therapies.
×
